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Differential regulation of the regulatory subunits of 
CAMP-dependent protein kinase isozymes correlates 
with the growth inhibitory effect of site-selective S- 
Cl-CAMP demonstrated in cancer cell lines (Ally, S., 
Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, 
D., 0greid, D., Doskeland, S. O., Jahnsen, T., and Cho- 
Chung, Y. S. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 
6319-6322). Such selective modulation of protein ki- 
nase isozyme regulatory subunits was also found in the 
S-Cl-CAMP-induced inhibition of both transformation 
and transforming growth factor (Y (TGFa) production 
in Ki-ras-transformed rat kidney fibroblasts (Tortora, 
G., Ciardiello, F., Ally, S., Clair, T., Salomon, D. S., 
and Cho-Chung, Y. S. (1989) FEBS Lett. 242, 363- 
367). In this work, we have demonstrated that 8-W 
CAMP antagonizes the TGFa effect in TGF+trans- 
formed mouse mammary epithelial cells (NOG- 
8TFC17) at the level of gene expression for CAMP 
receptor protein isoforms, RI and RI1 (the regulatory 
subunits of protein kinase isozymes). Northern blot 
analysis demonstrated that in the transformed NOG- 
8TFC17 cells, compared with the nontransformed 
counterpart NOG-8 cells, the mRNA levels for the RI, 
CAMP receptor protein markedly increased, whereas 
the mRNA levels for the RII, and RIIB CAMP receptor 
proteins decreased. 8-Cl-CAMP, which induced growth 
inhibition and phenotypic reversion in NOG-8TFC17 
cells, caused an inverse change in the mRNA patterns 
of the CAMP receptor proteins; RI, CAMP receptor 
mRNA sharply decreased to levels comparable with 
that of the nontransformed NOG-8 cells, whereas RII, 
mRNA increased to a level even greater than that in 
the NOG-8 cells. In addition, one mRNA species of RII, 
increased, whereas the other RII, mRNA species de- 
creased during the treatment. The mRNA level for the 
catalytic subunit of protein kinase, however, did not 
change during 8-Cl-CAMP treatment. In addition, 8- 
Cl-CAMP brought about a reduction in both TGFa 
mRNA and protein levels. These coordinated changes 
in the expression of the CAMP receptor proteins and 
TGFa were not observed during cis-hydroxyproline- 
or TGF&induced growth inhibition of the NOG- 
* The costs of publication of this article were defrayed in part by 
the payment of page charges. This article must therefore be hereby 
marked “aduertisement” in accordance with 18 U.S.C. Section 1734 
solelv to indicate this fact. 
$ ?o whom correspondence should be addressed: Bldg. 10, Rm. 
5B38, Lab. of Tumor Immunology and Biology, NCI, NIH, Bethesda, 
MD 20892. 
8TFC17 cells. Thus, the antagonistic effect of 84% 
CAMP toward TGFcr-induced transformation involves 
modulation of the expression of a specific set of cellular 
genes. 
In mammalian cells, CAMP functions through two classes 
of CAMP-dependent protein kinases (1, 2), designated types I 
and II. Type I and II protein kinases are distinguished by 
their regulatory subunits (RI and RII, respectively’ (3, 4). 
Four different regulatory subunits (RI, (previously designated 
RI) (5), RI/3 (6), RII, (RIIb4) (7), and RIIB (RIL) (8)) have 
now been identified at the gene/mRNA level (see Ref. 9 for 
nomenclature). Two different catalytic subunits (C, (10) and 
Cp (11, 12)) have also been identified; however, preferential 
coexpression of either one of these catalytic subunits with 
either the type I or II protein kinase regulatory subunit has 
not been found (12). 
Recently, we discovered that site selective CAMP analogs, 
which show a preference for binding to type II rather than 
type I protein kinase of purified preparations in vitro (13,14), 
provoke potent growth inhibition, differentiation, and reverse 
transformation in a broad spectrum of human and rodent 
cancer cell lines (15-17). We have also demonstrated that the 
antineoplastic effects of site-selective 8-Cl-CAMP are associ- 
ated with an antagonistic activity on the effects of exogenous 
transforming growth factor (Y (TGFol) in normal rat kidney 
fibroblasts and on the production of TGFol in Ki-ras-trans- 
formed rat kidney cells (18). 
TGFa is a potent mitogen for fibroblasts and epithelial 
cells (19) and has been implicated in the autocrine growth of 
rodent and human tumor cells. In fact, enhanced expression 
of TGFa has been detected in a number of rodent and human 
breast cancer cell lines and in a majority of primary rodent 
and human breast carcinomas (20-24). In addition, the ability 
of estrogens to stimulate the growth of estrogen-dependent 
breast cancer cells may be related in part to an increased 
’ The abbreviations used are: RI and RII, regulatory subunits of 
isozymes I and II of CAMP-dependent protein kinase, respectively; 
TGFa, transforming growth factor 0~; DMEM, Dulbecco’s modified 
minimal essential medium; FBS, fetal bovine serum; CHP, 4-k- 
hydroxy-L-proline; RIA, radioimmunoassay; RRA, radioreceptor as- 
say; EGF, epidermal growth factor; bp, base pair(s); kb, kilobase 
pair(s); HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid; 
MOPS, 3-(N-morpholino)propanesulfonic acid; 8-N$AMP, 8-azi- 
doadenosine 3’:5’-monophosphate. 
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CAMP and TGFas Antagonism 1017 
production of TGFa in response to estrogen stimulus (20, 21, 
24). Also, experimentally, overexpression of the human TGFa 
gene in an expression vector plasmid successfully converts in 
vitro (25) an immortalized nontransformed mouse mammary 
epithelial cell clone (NOG-8) to a transformed phenotype 
(NOG-8TFC17) that produces tumors in viuo (25). NOG-8 
TFC17 cells, therefore, represent a novel in vitro system to 
investigate the regulatory mechanisms underlying cell prolif- 
eration and transformation and to eventually identify the 
antitransforming factor that has the ability to interfere with 
the production and/or action of TGFcL 
In this work, we have examined the effect of 8-Cl-CAMP 
on TGFLu-induced transformation of NOG-8TFC17 cells in 
comparison with that of two other known growth inhibitors, 
cis-hydroxyproline (26, 27) and TGFP (28, 29). The results 
are correlated with the expression of CAMP-dependent pro- 
tein kinase isozymes and TGFa production in NOG-8TFC17 
cells. 
EXPERIMENTAL PROCEDURES 
Materials-8-Cl-cAMP/Na+ and NG-benzyl-CAMP were kindly 
provided by R. K. Robins (Nucleic Acid Research Institute). Pepsta- 
tin, antipain, chymostatin, leupeptin, and soybean trypsin inhibitor 
were obtained from Sigma. 8-N3[3ZP]cAMP (60.0 Ci/mmol) and iz51- 
labeled protein A (30 mCi/mg) were obtained from ICN Pharmaceu- 
ticals, Inc. Dulbecco’s modified minimal essential medium (DMEM), 
fetal bovine serum (FBS), trypsin/EDTA solution, penicillin/strep- 
tomycin solution, and L-glutamine were obtained from GIBCO. 4-cis 
Hydroxy-L-proline (CHP) was obtained from Calbiochem. Porcine 
TGFp was purchased from R and D systems. 
NOG-8 cells are a subclone of a nontransformed nontumorigenic 
mouse mammary epithelial cell line (NMuMG) originally isolated 
from the mammary gland of NaMru mice (30,31). NOGdTFCM is a 
clone of NOG-8 cells that had been transfected and transformed with 
a plasmid (pSVTGFa) that contains the entire coding region of 
human TGFa cDNA and the SV40 promoter (25). 
Cell Culture-NOG-8 and NOG-8TFC17 cells were grown in a 
medium consisting of DMEM supplemented with 10% FBS, 20 mM 
HEPES, pH 7.4, 4 mM glutamine, 100 pg/ml streptomycin, and 100 
units/ml penicillin in a humidified atmosphere of 95% air and 5% 
CO* at 37 “C. For monolayer growth, the cells (2 X lo4 cells/well) 
were plated in multiwell cluster dishes (Costar) in 2 ml of DMEM 
containing 10% FBS. At 24 h after seeding (day 0), the medium was 
changed, and fresh medium was added every 48 h thereafter. Starting 
at day 0, 8-Cl-CAMP, CHP, or TGFp was added when the medium 
was replenished. At the indicated times, cells were harvested by 
trypsinization (GIBCO), and cell counts were performed on a ZBI 
Coulter Counter. For soft agar growth, the cells (2 X lo4 cells/dish) 
were seeded in 1 ml of 0.3% Difco Nobel agar supplemented with 
DMEM and 10% FBS. This suspension was layered over 1 ml of 0.8% 
agar/medium base layer in 35-mm dishes (Costar) and treated with 
various concentrations of 8-Cl-CAMP, CHP, or TGFP. After 14 days, 
the cells were stained with nitro blue tetrazolium, and colonies larger 
than 50 pm were counted with an Artek Model 880 colony counter. 
Preparation of Conditioned Medium-The cells were grown to 50- 
60% confluency in 10% FBS containing DMEM in T-150 flasks 
(Costar), washed twice in serum-free medium, and cultured in PC-l 
serum-free medium (Ventrex) for an additional 48 h in the absence 
or presence of various concentrations of 8-Cl-CAMP, CHP, TGFP. 
Conditioned medium (40 ml/flask) was acidified with 0.4 N HCl and 
concentrated on a Cls Sep-Pak reverse-phase minicolumn (Waters 
Instruments, Inc.) as previously described (21,22). 
Radioimmunoassay (RIA) and Radioreceptor Assay (RRA) for 
TGFa-The levels of immunoreactive TGFa were determined using 
a liquid-phase competitive RIA with a polyclonal rabbit anti-rat 
TGFa antiserum that is specific for TGFa and fails to recognize 
mouse or human epidermal growth factor (EGF) as previously de- 
scribed (22, 23). Labeled rat synthetic 1251-TGF~, rabbit anti-TGFa 
antiserum, and other reagents were purchased from Biotope Inc. EGF 
receptor-competing activity was analyzed as previously described (23) 
by using monolayer cultures of 184AlN4 cells, a human mammary 
epithelial cell line that possesses approximately lo6 EGF receptor 
sites/cell. The amount of TGFa equivalent units in the samples was 
calculated in comparison with the competition curves produced by 
different concentrations of unlabeled human TGFa (Bachem) with 1 
rig/ml mouse iz51-EGF (specific activity = 100 &i/pg; Amersham 
Corp.). 
Isolation of Total RNA and Northern Blot Analysis-The cells (10s 
washed twice with phosphate-buffered saline) were lysed in 4.2 M 
guanidine isothiocyanate containing 25 mM sodium citrate, pH 7.0, 
0.5% Sarkosyl (N-lauroylsarcosine/Na+), and 0.1 M P-mercaptoeth- 
anol; the lysates were homogenized; and total cellular RNA was 
sedimented through a CsCl cushion (5.7 M CsCl, 0.1 M EDTA) as 
described by Chirgwin et al. (32). Total cellular RNA containing 20 
mM MOPS, pH 7.0, 50% formamide, and 6% formaldehyde was 
denatured at 65 “C for 10 min and electrophoresed through a dena- 
turing 1.2% agarose, 2.2 M formaldehyde gel. Ethidium bromide 
staining of the gels revealed that equivalent amounts of RNA were 
present in all of the samples. The gels were then transferred to 
Biotrans nylon membranes (ICN Biomedicals) by the method of 
Thomas (33) and hybridized to the following “P-labeled nick-trans- 
lated cDNA probes: a 406-bp EcoRI-ApaI restriction fragment derived 
from a human TGFol cDNA clone; pTGF-Cl (34); a 600-bp I’stI 
restriction fragment of the mouse CAMP-dependent progein kinase 
type I regulatory subunit, RI, cDNA clone (35); a 1600-bp BamHI 
restriction fragment of the human CAMP-dependent protein kinase 
type II regulatory subunit, RIIB cDNA clone (36); a 1650-bp EcoRI 
restriction fragment of the human CAMP-dependent protein kinase 
type II regulatory subunit, RII, cDNA clone (37); and 600-bp EcoRI 
restriction fragment of the mouse CAMP-dependent protein kinase 
catalytic subunit, C, cDNA clone (38). 
RESULTS 
Effect on Cell Growth-The effect of 8-Cl-CAMP on the 
growth of the transformed NOG-8TFC17 cells and nontrans- 
formed counterpart NOG-8 cells is shown in Fig. 1. 8-Cl- 
CAMP inhibited the monolayer growth of the NOG-8TFC17 
cells in a concentration-dependent manner. At 10 and 25 pM, 
the analog produced 50 and 70% growth inhibition, respec- 
tively, when compared with that in the untreated control cells 
(Fig. IA). In contrast, up to a 50 pM concentration of 8-Cl- 
CAMP produced no growth inhibition in the nontransformed 
NOG-8 cells. A greater degree in the growth inhibitory effect 
of 8-Cl-CAMP was shown when the transformed NOG- 
8TFC17 cells were grown in soft agar. At 5 pM, the analog 
produced over 90% inhibition of colony formation compared 
with that in the untreated control cells (Fig. 1B). Fig. 1 also 
shows the effect of CHP on the growth of the NOG-8 and 
NOG-8TFC17 cells. The proline analog CHP has been shown 
to inhibit the growth of rat mammary tumors in uiuo (26) and 
of virally transformed rodent cell lines in vitro (27). CHP 
exhibited growth inhibition in both the NOG-8 and NOG- 
8TFC17 cells, although it produced a more potent effect on 
the transformed cells than on the nontransformed cells (Fig. 
1C). At 25 pg/ml, CHP inhibited over 90% of the colony 
formation of the NOG-8TFC17 cells in soft agar (Fig. 1D). 
FIG. 1. Effect of 8-Cl-CAMP and CHP on monolayer (A and 
C) and soft agar (B and D) growth of NOG-8 and NOG- 
8TFC17 cells. The data represent an average & S.D. of four experi- 
ments. Colonies in the untreated controls were 1300 +55/dish. 
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1018 CAMP and TGFcv Antagonism 
TGF/3 at l-5 rig/ml produced a weak growth inhibitory effect 
(-30% inhibition) on both NOG-8 (in monolayer culture) and 
NOG-8TFC17 (in monolayer culture or in soft agar) cells. 
Time courses of the growth inhibition produced by 8-Cl- 
CAMP (25 pM) and CHP (30 pg/ml) in the NOG-8TFC17 cells 
in monolayer culture are shown in Fig. 2. The growth inhibi- 
tion by these analogs required two to three population dou- 
blings. On day 3, both analogs produced a 30-50% growth 
inhibition; and by day 4, a 60-70% growth inhibition was 
achieved compared with that in the untreated control cells. 
The growth inhibition in NOG-8TFC17 cells brought about 
by 8-Cl-CAMP or CHP accompanied distinct morphological 
changes. The growth-arrested cells exhibited a reverted mor- 
phology that resembled that of nontransformed NOG-8 cells 
(data not shown). 
Effect of TGFcr Production-We examined whether the 
growth inhibitory effects of 8-U-CAMP, CHP, and TGFP on 
the NOG-8TFC17 cells are associated with a specific interfer- 
ence by these agents on TGFa production. The conditioned 
media (see “Experimental Procedures”) were collected from 
the culture of the NOG-8TFC17 cells, and the levels of the 
immunoreactive and biologically active TGFo( were measured 
by RIA and RRA, respectively. As shown in Table I, 8-Cl- 
CAMP caused a decrease of TGFcv production in the trans- 
formed NOG-8TFC17 cells in a concentration-dependent 
manner. Twenty and sixty percent reductions in TGFa pro- 
duction were achieved by 25 and 50 pM 8-Cl-CAMP, respec- 
tively. 8-Cl-CAMP (5 pM) and p-benzyl-CAMP (15 pM) each 
alone had no inhibitory effect on TGFa production. However, 
Time (Days) 
FIG. 2. Temporal course of effect of S-Cl-CAMP and CHP 
on monolayer growth of NOG-8TFCl7 cells. The data represent 
an average + S.D. of four experiments. 
TABLE 1 
Effect of 8-Cl-CAMP, CHP, and TGFfi on TGFm production 
in NOG-8TFCl7 cells 
The TGFcr protein from the concentrated conditioned medium 
(CM) was evaluated in a TGFn-specific RIA and in an EGF/TGFct 
RRA as previously described (22, 23). The values represent the mean 
k SD. of four experiments. The values in parentheses are the per- 
centages. 
TCFn m CM 
Treatment 
RIA RRA 
None 
8-Cl-CAMP 
25 /.LM 
50 pM 
CHP 
25 pg/ml 
50 pg/ml 
TGF/;I (1 r&ml) 
n&‘/l Ox cells/48 h 
660 f 60 (100) 680 f 66 (100) 
550 + 47 (83) 530 f 52 (78) 
250 + 20 (38) 250 + 20 (37) 
640 k 55 (97) 670 + 63 (99) 
570 + 55 (86) 590 + 57 (87) 
680 + 62 (103) 650 -c 63 (96) 
these analogs in combination at these respective concentra- 
tions exerted as much inhibitory effect as that produced by 
these analogs alone at higher concentrations (-50 pM), dem- 
onstrating a synergistic effect (data not shown). 
In contrast, both CHP and TGFp at the concentrations 
that demonstrate growth inhibition exhibited little or no 
effect on the TGFo( production in NOG-8TFC17 cells (Table 
I). The results in Table I indicate that the growth inhibitory 
effect of 8-Cl-CAMP is associated with inhibition of TGFa 
production, whereas that of CHP and TGF/? does not involve 
interference of TGFL~ production. 
mRNAs of CAMP Receptor Proteins and TGFor-The effects 
of 8-Cl-CAMP, CHP, and TGFP on the mRNA levels of the 
regulatory (RI,, RII,,, and RI&,) and catalytic (C,) subunits of 
CAMP-dependent protein kinases and TGFcv were determined 
in the NOG-8TFC17 cells. The RNA filters prepared were 
probed with ‘“P-labeled cDNAs of RII,,, RII,,, RI,,, and TGFcu; 
Northern blot analysis is shown in Fig. 3. The results are 
expressed in relation to the mRNA levels in the nontrans- 
formed NOG-8 cells (Fig. 3, lower). The human RII, cDNA 
probe detected 6.0- and 2.2-kb mRNA species in the NOG-8 
cells (Fig. 3, upper lane NOG-8). Transformation with TGFo( 
caused a 70% decrease in both the 6.0- and 2.2-kb RII, mRNA 
species (lane C). 8-Cl-CAMP treatment of the transformed 
cells brought about a further decrease in the 6.0-kb mRNA, 
but an increase in the 2.2-kb mRNA species (lane 8-C% 
* I) ) * @ -3.2 Kb 
2.2 Kb- b k y . (. .@I*# -1.7Kb 
R=P TGFa 
6 (I b() -2.3 Kb 
- 
N C 6- C T 
Go c’ F P 
6 , P , 
NOG-6-TFC17 
N C6-C T 
0 Cl H G 
G PF 
6 , P , 
NOG-6-TFC17 
Lane mRNA Levels (Relative level) 
R&t RQ RLI TGFa 
NOG-6 1.0 +o.i I .0+0.1 1.0~0.1 N.D. 
NOG- C 0.2 -Co.02 0.5*0.05 10.0~1.0 10.0~1.0 
6-TF- 
Cl7 6-Cl 0.07~0.01 6.oeo.6 1.5eo.2 1.0*0.1 
CHP 0.2 eo.02 0.6-cO.09 4.3eo.4 6.OkO.6 
TGFfi 0.15zkO.02 3.OkO.3 9.2 to.9 12.321.3 
FIG. 3. Northern blot analysis of RI,, RII,, and RIIB CAMP 
receptor and TGFa mRNAs in NOG-8 (untreated) and NOG- 
STFCl7 cells untreated and treated with S-Cl-CAMP (25 PM), 
CHP (30 pg/ml), or TGFB (1 rig/ml) for 3 days. Control and 
treated cells were harvested, and total RNA was extracted by the 
guanidine isothiocyanate method as described under “Experimental 
Procedures.” Twenty micrograms of total RNA/lane were run on 
1.2% agarose-formaldehyde gels and blotted onto nylon membranes. 
Untreated control cells (lane C) were also grown for 3 days. The data 
in the table represent quantification by densitometric scanning of the 
autoradiograms. The data are expressed relative to the levels in 
nontransformed NOG-8 cells, which are set equal to 1 arbitrary unit. 
The TGFcr data are expressed relative to the levels in the untreated 
control NOG-8TFCl7 cells, which are set equal to 10 arbitrary units. 
ND., not detectable. The data represent an average k S.D. of four 
experiments. 
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CAMP and TGFcY Antagonism 1019 
CAMP); in total quantity, RII, mRNA decreased to 30% of 
that in the untreated transformed cells (Fig. 3). CHP and 
TGFP treatment brought about little or no effect on the levels 
of the 6.0- and 2.2-kb RII, mRNA species (Fig. 3). The human 
RIIB cDNA detected a 1.9-kb mRNA species. The RII, mRNA 
level decreased by 50% in the transformed NOG8TFC17 cells 
(lane C) compared with that in the nontransformed cells (lane 
NOG-8). 8-Cl-CAMP treatment of NOG-8TFC17 cells brought 
about a 16-fold increase in the RIIB mRNA level over that in 
the untreated control cells (Fig. 3). CHP caused little or no 
effect on the RIIp mRNA level, but TGFp caused a substantial 
increase (6-fold) in the RIIp mRNA level (Fig. 3). The mouse 
RI, cDNA probe detected a 3.2- and 1.7-kb mRNA species. 
Both the 3.2- and 1.7-kb mRNA species markedly increased 
(-IO-fold) in the transformed NOG-8TFC17 cells (lane C) 
compared with the nontransformed cells (lane NOG-8). 8-Cl- 
CAMP caused a marked decrease in both the 3.2- and 1.7-kb 
mRNA levels comparable to that in the nontransformed cells 
(Fig. 3). CHP also decreased the RI, mRNA level by 60%, but 
TGFP caused little or no effect on RI, mRNA (Fig, 3). The 
mouse C, cDNA probe detected a 2.4-kb mRNA species in 
the transformed and nontransformed cells in a similar quan- 
tity, and treatment with 8-Cl-CAMP, CHP, or TGFp caused 
no change in the mRNA levels (data not shown). 
The human TGFa cDNA probe detected a 2.3-kb mRNA 
species in the transformed NOG-8TFC17 cells (Fig. 3, upper, 
lane C), but not in the nontransformed cells (lane NOG-8). 
8-Cl-CAMP treatment brought about a 90% reduction in the 
TGFa mRNA level of NOG-8TFC17 cells (Fig. 3), whereas 
CHP decreased the TGFa mRNA level only by 20%, and 
TGF@ caused a slight increase in the TGFa mRNA level (Fig. 
3). 
In previous work, we demonstrated that site l- and 2- 
selective CAMP analogs, which in combination produce syn- 
ergistic enhancement of binding to type II rather than type I 
CAMP-dependent protein kinase (13, 14), also produces a 
synergistic growth inhibitory effect (l&17,39). We examined 
whether such synergism exists between 8-Cl-CAMP (site l- 
selective) and NG-benzyl-CAMP (site 2-selective) in changing 
levels of mRNAs for CAMP receptor proteins and TGFa in 
NOG-8 TFCl7 cells. When cells were treated with 5 pM 8-Cl- 
CAMP, which alone gave a 20% growth inhibition (Fig. l), the 
mRNA levels of CAMP receptors and TGFL~ were not signif- 
icantly different from those in the untreated control cells 
(Table II). However, 5 pM 8-Cl-CAMP in combination with 
TABLE II 
Effect of CAMP analogs on mRNA levels for CAMP receptor proteins 
and TGFo( in NOG-8TFCl7 cells 
Northern blot analysis was performed, and the data were quantified 
by densitometric tracing of the autoradiograms as described in the 
legend to Fig. 3. 
mRNA levels (relative values) 
Treatment 
RII, RII, RI, TGFa 
None” 0.2 f 0.02 0.5 + 0.05 10.0 k 1.0 10.0 + 1.0 
8-Cl-CAMP 
25 PM 0.07 + 0.01 8.0 + 0.8 1.5 + 0.2 1.0 f 0.1 
5w’M 0.2 + 0.02 0.7 + 0.08 8.5 + 0.8 9.0 + 0.9 
N’-Benzyl-CAMP 
(15 PM) 0.2 + 0.02 0.5 + 0.05 10.0 + 1.0 10.0 + 1.0 
8-Cl-CAMP (5 jtM) 
+N’-benzyl-CAMP 
(15 PM) 0.07 + 0.01 7.8 + 0.8 2.5 + 0.3 1.5 f 0.2 
N’-Benzyl-CAMP 
(50 PM) 0.10 + 0.01 5.0 + 0.7 4.5 + 0.5 5.0 + 0.5 
’ The data are expressed relative to the levels in nontransformed 
NOG-8 cells, which are set equal to 1 arbitrary unit (see Fig. 3) and 
represent an average -C S.D. of three experiments. 
15 PM NG-benzyl-CAMP brought about changes in these 
mRNA levels to an extent similar to that produced by higher 
concentrations of ~-U-CAMP (25 pM) alone (Table II). In 
addition, 15 FM NG-benzyl-CAMP alone neither exerted 
growth inhibition or changed these mRNA levels (Table II). 
However, 50 pM NG-benzyl-CAMP, which demonstrated a 
moderate growth inhibitory effect, brought about changes in 
these mRNA levels to a lesser extent than that produced by 
25 pM 8-Cl-CAMP (Table II). 
DISCUSSION 
Our study presents the first evidence of the CAMP antago- 
nism for TGFa at the level of cellular gene expression. The 
data presented in this study show that there is an antagonistic 
interaction between TGFa and 8-Cl-CAMP in the regulation 
of mammary epithelial cell proliferation. TGFa induces trans- 
formation in an immortalized population of mouse mammary 
epithelial cells (25), whereas 8-Cl-CAMP, a potent growth 
inhibitor for a spectrum of human cancer cell lines (15-17), 
can reverse such transformation, This antagonism between 
TGFa and 8-Cl-CAMP is expressed in the modulation of the 
genes for different species of the CAMP receptor proteins. 
The transformation of mammary epithelial cells with TGFa 
resulted in a marked increase in the RI, CAMP receptor 
mRNA level along with a decrease in the RII, and RIIB CAMP 
receptor mRNA levels. In the reverse transformation by 8- 
Cl-CAMP, the RI, mRNA level decreased, whereas one species 
of RII, mRNA and RIIB mRNA levels sharply increased, 
converting the RII/RI CAMP receptor mRNA ratio to a value 
similar to that in nontransformed mammary epithelial cells. 
Thus, transformation by TGFa brought about a disruption 
in the normal mRNA patterns of CAMP receptor species, and 
8-Cl-CAMP restored the normal CAMP receptor mRNA pat- 
terns in the mammary epithelial cells. The changing patterns 
of CAMP receptor mRNAs brought about by 8-Cl-CAMP are 
the specific effects of the analog rather than a nonspecific 
event related to growth inhibition in general since two other 
known growth inhibitors, namely CHP (a proline analog) and 
TGFP, inhibited the growth of the transformed mammary 
epithelial cells without reverting the abnormal CAMP receptor 
mRNA patterns to the normal patterns. 
That these effects of 8-Cl-CAMP are due to the interaction 
of this CAMP analog with type II CAMP-dependent protein 
kinase is supported by the synergistic effect observed with 8- 
Cl-CAMP and NG-benzyl-CAMP in combination (Table II). 
Such synergism between site l- and 2-selective CAMP analogs 
has been previously demonstrated with purified preparations 
of protein kinase in vitro (13,14) and in the growth inhibition 
and differentiation induced in cancer cells by these CAMP 
analogs (15-17, 39). Moreover, in the growth inhibition in- 
duced by 8-Cl-CAMP of LS-174T human cancer cells, there 
was rapid translocation of RIIB CAMP receptor protein from 
the cytoplasm to the nucleus that preceded increased tran- 
scription of the RIIB gene with decreased transcription of the 
RI, gene (40). Based on these previous findings, we interpret 
our present results of the changing levels of mRNAs for CAMP 
receptor protein to be due to changes in transcription rather 
than to effects on mRNA stability. 
Concomitantly, with these changes in mRNAs for the 
CAMP receptor proteins, 8-Cl-CAMP also brought about a 
reduction in the TGFa mRNA level. In these cells, TGFa 
production is driven by the SV40 promoter. Whether the 
inhibitory effects of 8-Cl-CAMP were directed against the 
SV40 promoter is not known at present. A CAMP- and phorbol 
ester-responsive element (activator protein P)-binding se- 
quence has been identified in the transcription enhancer of 
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the SV40 promoter (41). However, no negative control by 
CAMP of such a viral promoter is known. 
16. Tortora, G., Tagliaferri, P.k Clair, T., Colamonici, O., Neckers, 
L. M., Robins, R. K., and Cho-Chung, Y. S. (1988) Blood 71, 
230-233 The results presented here suggest that 8Cl-CAMP, binding 
to its specific site at CAMP receptor proteins (40) by substi- 
tuting for endogenous CAMP, modulates its own receptor 
expression as well as those of proliferative signal(s), thereby 
regulating cell prohferation and transformation. Furthermore, 
the nrecise antagonism between TGFa and 8-Cl-CAMP dem- 
onstrated at theievel of cellular gene expression in the growth 
control of the experimental mammary epithelial cells suggests 
the possibility that such antagonism may be a fundamental 
mechanism for the growth regulation of human cancers. 
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